It Is Suitable For Those in Tokyo seeking treatment for anti-aging and healing support
For pilot studies, method development, or any protocol that will not consume 100mg inside a sensible in-use window, the smaller vial is the technically preferable choice rather than merely the cheaper one
The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination
But, in my view, all those will be to little to late
It gave me an extra boost of energy